{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:08:26Z","timestamp":1781629706298,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Yunnan Zhu Xiaofan Expert Workstation","award":["202105AF150070"],"award-info":[{"award-number":["202105AF150070"]}]},{"name":"Yunnan Zhu Xiaofan Expert Workstation","award":["202105AF150070"],"award-info":[{"award-number":["202105AF150070"]}]},{"name":"Sichuan Science and Technology Program","award":["2022YFS0622, 2022YFS0622-B4"],"award-info":[{"award-number":["2022YFS0622, 2022YFS0622-B4"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This ambispective cohort study evaluates the effectiveness of cardioprotective strategies in reducing anthracycline-induced cardiotoxicity in pediatric patients with acute lymphoblastic leukemia (ALL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center, historically controlled ambispective cohort study at Kunming Children\u2019s Hospital. Children with newly diagnosed ALL treated with the CCLG-ALL2018 protocol between May 2018 and May 2020 comprised the retrospective historical control cohort (no dexrazoxane). After institutional adoption of dexrazoxane, consecutive eligible patients treated between May 2020 and May 2022 were prospectively enrolled and followed according to a prespecified cardiac monitoring schedule. The exposure (use of dexrazoxane) was determined by calendar time rather than randomization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The combination therapy group exhibited significantly lower rates of electrocardiogram and echocardiogram abnormalities (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01, respectively), suggesting a notable cardioprotective effect. Although baseline cardiac markers did not show significant differences between the groups, post-treatment levels of cardiac troponin T were significantly improved in the combination therapy group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Additionally, trends toward improved left ventricular ejection fraction and Creatine Kinase-Myocardial Band levels were observed, although these did not reach statistical significance. Importantly, the use of the cardioprotective agent did not lead to a significant increase in adverse reactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Incorporating a cardioprotective strategy into pediatric ALL treatment protocols appears to lower the risk of anthracycline-induced cardiotoxicity without compromising safety, hence boosting patient outcomes. These findings should be interpreted in light of the historically controlled, nonrandomized design and potential time-related confounding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-025-00420-8","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T11:22:29Z","timestamp":1767957749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dexrazoxane Cardioprotection in pediatric ALL: a historical control cohort study"],"prefix":"10.1186","volume":"12","author":[{"given":"Li","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiJin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qulian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"1","key":"420_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ped.13457","volume":"60","author":"M Kato","year":"2018","unstructured":"Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60(1):4\u201312.","journal-title":"Pediatr Int"},{"issue":"1","key":"420_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1389200218666171101124931","volume":"19","author":"JE Megias-Vericat","year":"2018","unstructured":"Megias-Vericat JE, Martinez-Cuadron D, Herrero MJ, et al. Pharmacogenetics of metabolic genes of anthracyclines in acute myeloid leukemia. Curr Drug Metab. 2018;19(1):55\u201374.","journal-title":"Curr Drug Metab"},{"issue":"7","key":"420_CR3","first-page":"2175","volume":"22","author":"MA Nicolazzi","year":"2018","unstructured":"Nicolazzi MA, Carnicelli A, Fuorlo M, et al. Anthracycline and trastuzumab-indu-ced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci. 2018;22(7):2175\u201385.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"420_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/EDBK_100015","volume":"38","author":"S Armenian","year":"2018","unstructured":"Armenian S, Bhatia S. Predicting and preventing anthracycline-related cardiotoxicity. Am Soc Clin Oncol Educ Book. 2018;38:3\u201312.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"420_CR5","volume":"5","author":"S Ganatra","year":"2019","unstructured":"Ganatra S, Nohria A, Shah S, et al. Upfront dexrazoxane for the redu-ction of anthracycline-induced cardiotoxicity in adults with preexisting cardiom-yopathy and cancer: a consecutive case series. Cardio-Oncol. 2019;5:1.","journal-title":"Cardio-Oncol"},{"issue":"11","key":"420_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008209","volume":"14","author":"E Jirkovsk\u00fd","year":"2021","unstructured":"Jirkovsk\u00fd E, Jirkovsk\u00e1 A, Bavlovi\u010d-Pisk\u00e1\u010dkov\u00e1 H, et al. Clinically T-ranslatable prevention of anthracycline cardiotoxicity by dexrazoxane is medi-ated by topoisomerase II beta and not metal chelation. Circ Heart Fail. 2021;14(11):e008209.","journal-title":"Circ Heart Fail"},{"key":"420_CR7","first-page":"15","volume":"5","author":"LM Kopp","year":"2019","unstructured":"Kopp LM, Womer RB, Schwartz CL, et al. Effects of Dexrazoxane -on doxorubicin-related cardiotoxicity and second malignant neoplasms in Childre -n with osteosarcoma: a report from the children\u2019s oncology group. Cardiooncology. 2019;5:15.","journal-title":"Cardiooncology"},{"issue":"1","key":"420_CR8","volume":"7","author":"CV Noel","year":"2021","unstructured":"Noel CV, Rainusso N, Robertson M, et al. Early detection of myoc-ardial changes with and without dexrazoxane using serial magnetic resonance im-aging in a pre-clinical mouse model. Cardio-Oncol. 2021;7(1):23.","journal-title":"Cardio-Oncol"},{"issue":"3","key":"420_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12012-019-09554-5","volume":"20","author":"BB Hasinoff","year":"2020","unstructured":"Hasinoff BB, Patel D, Wu X. The role of topoisomerase II\u03b2 in the mechanisms of action of the doxorubicin cardioprotective agent dexrazoxane. Cardiovasc Toxicol. 2020;20(3):312\u201320.","journal-title":"Cardiovasc Toxicol"},{"key":"420_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.911567","volume":"12","author":"Y Zhuang","year":"2022","unstructured":"Zhuang Y, Wu K, Zhu X, et al. Reduced dose intensity of daunorubicin duringremission induction for low-risk patients with acute lymphoblastic leukemia: a retrospective cohort study of the Chinese Children\u2019s Cancer Group. Front Oncol. 2022;12:911567.","journal-title":"Front Oncol"},{"issue":"9","key":"420_CR11","volume":"9","author":"EC De Baat","year":"2022","unstructured":"De Baat EC, Mulder RL, Armenian S, et al. Dexrazoxane for preventing or reducing cardioto-xicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst R-ev. 2022;9(9):CD014638.","journal-title":"Cochrane Database Syst R-ev"},{"issue":"2","key":"420_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/00148581-200507020-00001","volume":"7","author":"D Iarussi","year":"2005","unstructured":"Iarussi D, Indolfi P, Casale F, et al. Anthracycline-induced cardiotoxicity in children with can-cer: strategies for prevention and management. Paediatr Drugs. 2005;7(2):67\u201376.","journal-title":"Paediatr Drugs"},{"issue":"28","key":"420_CR13","doi-asserted-by":"publisher","first-page":"46663","DOI":"10.18632\/oncotarget.16944","volume":"8","author":"N Koleini","year":"2017","unstructured":"Koleini N, Kardami E. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget. 2017;8(28):46663\u201380.","journal-title":"Oncotarget"},{"key":"420_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102089","volume":"46","author":"D Li","year":"2021","unstructured":"Li D, Yang Y, Wang S, et al. Role of acetylation in doxorubicin-induced cardiotoxicity. Redox Biol. 2021;46:102089.","journal-title":"Redox Biol"},{"issue":"4","key":"420_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/hrt.2007.136093","volume":"94","author":"SE Lipshultz","year":"2008","unstructured":"Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525\u201333.","journal-title":"Heart"},{"issue":"6","key":"420_CR16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1007\/s00246-015-1176-7","volume":"36","author":"E Sadurska","year":"2015","unstructured":"Sadurska E. Current views on anthracycline cardiotoxicity in childhood cancer survivors. Pediatr Cardiol. 2015;36(6):1112\u20139.","journal-title":"Pediatr Cardiol"},{"issue":"25","key":"420_CR17","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2217\/fon-2018-0210","volume":"14","author":"P Reichardt","year":"2018","unstructured":"Reichardt P, Tabone MD, Mora J, et al. Risk-benefit of Dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol. 2018;14(25):2663\u201376.","journal-title":"Future Oncol"},{"issue":"1","key":"420_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2019.12.027","volume":"523","author":"X Yu","year":"2020","unstructured":"Yu X, Ruan Y, Huang X, et al. Dexrazoxane ameliorates doxoru-bicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in card-iomyocytes. Biochem Biophys Res Commun. 2020;523(1):140\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"420_CR19","first-page":"68","volume":"1","author":"AVS Macedo","year":"2019","unstructured":"Macedo AVS, Hajjar LA, Lyon AR, et al. Efficacy of De-xrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC: CardioOncology. 2019;1(1):68\u201379.","journal-title":"JACC: CardioOncology"},{"key":"420_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5107193","author":"X Yu","year":"2020","unstructured":"Yu X, Ruan Y, Shen T, et al. Dexrazoxane protects cardiomyocyte from Doxoru-bicin-induced apoptosis by modulating miR-17-5p. BioMed Res Int. 2020. https:\/\/doi.org\/10.1155\/2020\/5107193.","journal-title":"BioMed Res Int"},{"issue":"8","key":"420_CR21","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","volume":"34","author":"BL Asselin","year":"2016","unstructured":"Asselin BL, Devidas M, Chen L, et al. Cardioprotection and safety of Dexrazox-ane in patients treated for newly diagnosed T-cell acute lymphoblastic leuke-mia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children\u2019s Oncology Group randomized trial Pediatric Oncology Group 9404. J Clin Oncol. 2016;34(8):854\u201362.","journal-title":"J Clin Oncol"},{"key":"420_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","volume":"1257","author":"A Bhagat","year":"2020","unstructured":"Bhagat A, Kleinerman ES. Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention. Adv Exp Med Biol. 2020;1257:181\u201392.","journal-title":"Adv Exp Med Biol"},{"key":"420_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ijcard.2019.07.096","volume":"299","author":"D Filomena","year":"2020","unstructured":"Filomena D, Versacci P, Cimino S, et al. Echocardiographic long-term follow-up of adult survivors of pediatric cancer treated with Dexrazoxane-Anthracyclines a-ssociation. Int J Cardiol. 2020;299:271\u20135.","journal-title":"Int J Cardiol"},{"issue":"11","key":"420_CR24","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1634\/theoncologist.2010-0162","volume":"15","author":"DM Sepe","year":"2010","unstructured":"Sepe DM, Ginsberg JP, Balis FM. Dexrazoxane as a cardioprotectant in children receiving anthracyclines. Oncologist. 2010;15(11):1220\u20136.","journal-title":"Oncologist"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00420-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:31:25Z","timestamp":1781627485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-025-00420-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["420"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00420-8","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Kunming Children's Hospital (2022-03-049-K01). Informed consent was obtained from patients and guardians in the prospective intervention group, and a waiver of informed consent was granted for the retrospective control group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}